Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 3
2004 5
2005 5
2006 8
2007 18
2008 8
2009 24
2010 11
2011 13
2012 10
2013 16
2014 15
2015 7
2016 3
2017 4
2018 4
2019 4
2020 14
2021 15
2022 9
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 20234828

179 results

Results by year

Filters applied: . Clear all
Page 1
Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW. Hazell P, et al. Atten Defic Hyperact Disord. 2009 Dec;1(2):201-10. doi: 10.1007/s12402-009-0012-4. Epub 2009 Sep 23. Atten Defic Hyperact Disord. 2009. PMID: 20234828 Free PMC article. Clinical Trial.
Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM. Dittmann RW, et al. J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13. J Child Adolesc Psychopharmacol. 2011. PMID: 21488751 Clinical Trial.
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group. Dell'Agnello G, et al. Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28. Eur Neuropsychopharmacol. 2009. PMID: 19716683 Clinical Trial.
179 results